LGND Financial Facts

Weighted average number of common shares - basic: 20.19M
Lease exit and termination costs: 89K
See Full Income Statement

Current portion of deferred revenue: 556K
Total current assets: 17.74M
See Full Balance Sheet

Earnings History for Ligand Pharmaceuticals Inc. (LGND)

  |   Expand Research on LGND
Next EPS Date 8/7/13 *Est. EPS Growth Rate +128.6% *Last Qtr.
Average EPS % Beat Rate -124.3% Revenue Growth Rate +108.9% *Last Qtr.
Average % Move 1-Wk after EPS -3.9%    
Date  Qtr EPS Cons. Surprise Revs Cons. Estimize EPS/Revs Gd. % Since Details
5/8/13 Q113 $0.16$0.09 +$0.07$11.7M$10M N/A / N/A N/A +4.3% Details
2/13/13 Q412 $0.19N/A N/A $13.6M$12.9M N/A / N/A N/A +34.7% Details
11/5/12 Q312 -$0.01$0.04 -$0.05$6.4M$8.4M N/A / N/A N/A +62.3% Details
8/8/12 Q212 -$0.20-$0.02 -$0.18$5.7M$7.13M N/A / N/A N/A +54.2% Details
5/2/12 Q112 $0.07-$0.02 +$0.09$5.6M$8.02M N/A / N/A N/A +117.5% Details
2/7/12 Q411 $0.24N/A N/A $12.9M$3.9M N/A / N/A N/A +100.6% Details
11/8/11 Q311 -$0.20$0.01 -$0.21$5.7M$5.9M N/A / N/A = +133.5% Details
5/10/11 Q111 $0.48$0.05 +$0.43$3.9M$4.89M N/A / N/A = +143.3% Details
Like LGND Earnings? Also take a look at GSK, ONXX, PFE, ISRG

LGND Earnings News